Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

4.050 +0.060 (+1.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,430,543
Open 3.990
Bid (Size) 4.000 (200)
Ask (Size) 4.020 (800)
Prev. Close 3.990
Today's Range 3.960 - 4.200
52wk Range 1.410 - 4.200
Shares Outstanding 27,132,588
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+74.6%
+74.6%
1 Month
+62.7%
+62.7%
3 Month
+136.8%
+136.8%
6 Month
+114.3%
+114.3%
1 Year
+121.3%
+121.3%

More News

Read More
News headline image
Gain Therapeutics to Present at Neuroscience 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus ↗
Via Benzinga
Topics Economy
News headline image
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Gain Therapeutics, Inc. - Common Stock publicly traded?
Yes, Gain Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Gain Therapeutics, Inc. - Common Stock trade on?
Gain Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Gain Therapeutics, Inc. - Common Stock?
The ticker symbol for Gain Therapeutics, Inc. - Common Stock is GANX on the Nasdaq Stock Market
What is the current price of Gain Therapeutics, Inc. - Common Stock?
The current price of Gain Therapeutics, Inc. - Common Stock is 4.050
When was Gain Therapeutics, Inc. - Common Stock last traded?
The last trade of Gain Therapeutics, Inc. - Common Stock was at 12/09/25 04:00 PM ET
What is the market capitalization of Gain Therapeutics, Inc. - Common Stock?
The market capitalization of Gain Therapeutics, Inc. - Common Stock is 109.89M
How many shares of Gain Therapeutics, Inc. - Common Stock are outstanding?
Gain Therapeutics, Inc. - Common Stock has 110M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.